查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1877473

凝血障碍市场：依类型、治疗方法、检测方法、最终用户、国家及地区划分－全球产业分析、市场规模、市场占有率及2025-2032年预测

Coagulation Disorders Market, By Type, By Treatment, By Test, By End Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 387 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年凝血障碍市场规模为 105.6789 亿美元，从 2025 年到 2032 年以 6.8% 的复合年增长率成长。

凝血障碍市场的发展主要受出血和凝血障碍盛行率上升以及基因疗法和重组凝血因子等个人化医疗技术的进步所驱动。人工智慧在诊断和管理中的应用，透过预测分析和个人化监测优化治疗方案，预计将在预测期内为市场带来丰厚的机会。此外，数位化医疗解决方案透过促进远距监测和远距医疗咨询，提高了患者的便利性，增强了患者的依从性，并改善了治疗效果。然而，供应链中断和医疗基础设施的地域差异对市场扩张构成挑战。此外，高昂的治疗成本、监管方面的挑战以及新型检测技术普及速度缓慢也限制市场成长。

凝血障碍市场－市场动态

基因疗法和个人化医疗的日益普及

血友病和其他罕见出血性疾病历来需要反覆输注重组或血浆来源的凝血因子。然而，这些治疗费用昂贵，需要终身护理，并且有产生抑制剂的风险。基因疗法现在有望透过插入缺陷基因的功能性拷贝，一次性、长期地纠正凝血因子缺乏症。例如，2023年6月，美国FDA批准了用于治疗血友病A的Roctavian（BioMarin公司）和用于治疗血友病B的Hemgenix（CSL Behring/UniQure公司）等基因疗法。血友病A是一种罕见的遗传性疾病，其特征是凝血因子VIII（FVIII）缺乏，导致出血时间延长，并可能引发危及生命的併发症，例如无法控制的内出血和关节损伤。此外，个人化医疗透过根据个别基因谱量身定制治疗方案，进一步促进了这一转变，从而实现精准治疗并最大限度地减少不良反应。分子诊断技术的进步，包括基因检测和下一代定序 (NGS)，有助于早期诊断和患者分层，从而根据患者的特定特征匹配最合适的疗法，提高治疗效果。

凝血障碍市场細項分析：

全球凝血障碍市场按类型、治疗、检测、最终用户和地区进行细分。

依类型，市场分为五大类：血友病A、血友病B、血管性血友病、因子II、V、X、XII缺乏症及其他。血友病A是一种遗传性疾病，其特征是凝血因子VIII缺乏；血友病B则涉及因子IX缺乏，症状与之类似。血管性血友病是由于血管性血友病因子水平低下或缺陷所致，影响血液凝固并导致黏膜出血。因子II、V、X、XII缺乏症是一种罕见的凝血障碍，涉及其他凝血因子，导致不同程度的出血症状。

根据治疗方法，市场可分为三大类：补铁、输血和其他。补铁用于治疗慢性失血引起的贫血。输血则用于补充流失的血液并促进凝血因子恢復。凝血因子替代疗法、去氨加压素、抗凝血药物、基因疗法和非凝血因子疗法则根据疾病类型和严重程度製定个人化治疗方案。

凝血障碍市场－地域洞察

凝血障碍市场呈现明显的地域性趋势，主要受医疗基础设施、疾病盛行率和区域投资的影响。北美市场占据主导地位，这得益于凝血障碍的高发病率、完善的医疗保健体係以及强劲的研发活动。此外，血浆采集中心投资的增加也进一步推动了市场成长。欧洲市占率位居第二，德国、英国、法国、义大利和西班牙等国贡献显着。该地区的成长得益于广泛的研究合作、监管审批以及患者较高的健康意识。人口老化和诊断技术的进步也促使人们对凝血障碍治疗的需求不断增长。亚太地区是成长最快的地区，这主要得益于中国、印度和日本不断增长的医疗保健支出、快速的城市化进程以及不断扩大的医疗基础设施。由于医疗资源取得和健康意识的不足，中东、非洲和拉丁美洲等地区的成长速度相对较慢。然而，随着医疗保健技术的不断进步和国际合作的开展，这些地区也展现出巨大的发展潜力。

凝血障碍市场－竞争格局：

凝血障碍市场的竞争格局以多家全球领导者为特征，这些企业正透过先进的疗法和诊断解决方案推动创新。主要市场参与者致力于开发创新治疗方案，例如基因疗法、长效重组凝血因子、单株抗体和生物相似药，以改善患者的治疗效果和生活品质。例如，2024年4月，Haemonetics公司宣布其TEG 6s止血分析仪系统的Global Hemostasis-HN检测盒已获得美国食品药物管理局（FDA）的510(k)许可。这款新型检测盒扩展了TEG 6s系统的黏弹性检测功能，使其能够检测接受成人心血管手术和肝臟移植的全身肝素化患者。此外，无血浆重组产品的普及以及CRISPR等基因编辑技术的进步也是影响市场竞争格局的关键趋势。各公司也正在投资即时诊断工具和穿戴式凝血监测设备，推动医疗服务朝向个人化和便利化方向发展。为了拓展产品组合和区域影响力，企业之间进行策略合作、合併和收购已成为常态。

目录

第一章：凝血障碍市场概览

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
    • 凝血障碍市场概况（按类型划分）
    • 凝血障碍治疗市场概览
    • 凝血障碍市场概览（依测验分类）
    • 凝血障碍市场概览（依终端使用者划分）
    • 各国凝血障碍市场概况
    • 凝血障碍市场概况（按地区划分）
  • 竞争洞察

第三章：凝血障碍主要市场趋势

  • 凝血障碍市场驱动因素
    • 市场驱动因素的影响分析
  • 凝血障碍市场限制
    • 市场限制因素的影响分析
  • 凝血障碍市场机会
  • 凝血障碍市场未来趋势

第四章：凝血障碍产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：凝血障碍市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：凝血障碍市场概况

  • 凝血障碍市场占有率分析，2024 年
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：凝血障碍市场－按类型划分

  • 概述
    • 按类型分類的细分市场占有率分析
    • 血友病A
    • 血友病B
    • 血管性血友病
    • 因子 II、V、X、XII 缺乏症
    • 其他的

第八章：凝血障碍市场－依治疗方式划分

  • 概述
    • 按治疗方式分類的细分市场占有率分析
    • 铁补充剂
    • 输血
    • 其他的

第九章：凝血障碍市场－依检测方式划分

  • 概述
    • 测试版细分市场占有率分析
    • 全血球计数 (CBC)
    • 血小板聚集试验
    • 纤维蛋白原测定
    • 凝血酶原时间试验
    • 其他的

第十章：凝血障碍市场－依最终使用者划分

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 专科诊所
    • 诊断中心
    • 血库
    • 其他的

第十一章：凝血障碍市场－依地域划分

  • 介绍
    • 按地域分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美凝血障碍主要生产商
    • 北美市场规模及预测（按国家/地区划分）
    • 北美市场规模及预测（按类型划分）
    • 北美市场规模及预测（依治疗方式划分）
    • 北美市场规模及预测（按测试）
    • 北美市场规模及预测（依最终用户划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲凝血障碍主要生产商
    • 欧洲市场规模及预测（按国家/地区划分）
    • 欧洲市场规模及预测（按类型划分）
    • 欧洲市场规模及预测（依治疗方式划分）
    • 欧洲市场规模及预测（按测试）
    • 欧洲市场规模及预测（依最终用户划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区
    • 概述
    • 亚太地区凝血障碍主要生产商
    • 亚太市场规模及预测（依国家/地区划分）
    • 亚太市场规模及预测（按类型划分）
    • 亚太地区市场规模及预测（依治疗方式划分）
    • 亚太市场规模及预测（按测试）
    • 亚太市场规模及预测（依最终用户划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲凝血障碍主要生产商
    • 拉丁美洲市场规模及预测（按国家/地区划分）
    • 拉丁美洲市场规模及预测（按类型划分）
    • 拉丁美洲市场规模及预测（依治疗方式划分）
    • 拉丁美洲市场规模及预测（按测试）
    • 拉丁美洲市场规模及预测（按最终用户划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲凝血障碍主要生产商
    • MEA市场规模及预测（依国家/地区划分）
    • MEA市场规模及预测（按类型划分）
    • MEA市场规模及预测（依治疗方式划分）
    • MEA市场规模及预测（按测试）
    • MEA市场规模及预测（依最终用户划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 中东和非洲其他地区

第十二章：主要供应商分析－凝血障碍产业

  • 竞争格局分析
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Griflos SA
    • Hoffman-La Roche Ltd
    • Bio-Rad Laboratories
    • B Braun
    • Abbott
    • Bayer AG
    • Helena Laboratories
    • Fresenius Kabi
    • Haemonetics Corporation
    • VarmX BV
    • Biogen Inc.
    • Others

第十三章：360度AnalystView

第十四章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5697

Coagulation Disorders Market size was valued at US$ 10,567.89 Million in 2024, expanding at a CAGR of 6.8% from 2025 to 2032.

The coagulation disorders market is driven by increasing prevalence of bleeding and clotting disorders and advances in personalized medicine such as gene therapies and recombinant clotting factors. Integration of AI in diagnostics and management optimizes treatment plans through predictive analytics and individualized monitoring is expected to generate lucrative opportunities in the market over forecast period. Additionally, digital health solutions are increasing patient convenience, improving adherence, and enhancing outcomes by facilitating remote monitoring and telemedicine consultations. However, supply chain disruptions and geographic disparities in healthcare infrastructure pose challenges to market expansion. Moreover, high treatment costs, regulatory challenges, and slower adoption of novel testing technologies are also restraining the market growth.

Coagulation Disorders Market- Market Dynamics

Rising Adoption of Gene Therapies and Personalized Medicine

Hemophilia and other rare bleeding disorders have historically required repeated infusions of recombinant or plasma-derived clotting factors. Nevertheless, these treatments are expensive, need lifelong care, and carry a risk of inhibitor development. Gene therapies now offer the potential for one-time, long-lasting correction of coagulation factor deficiencies by inserting functional copies of defective genes. For instance, in June 2023, U.S. FDA have approved gene therapies such as Roctavian (BioMarin) for Hemophilia A and Hemgenix (CSL Behring/UniQure) for Hemophilia B. Hemophilia A is a rare genetic disorder characterized by a deficiency of clotting factor VIII (FVIII), which leads to prolonged bleeding and may cause life-threatening complications such as uncontrolled internal bleeding and joint damage. Additionally, personalized medicine further complements this shift by tailoring treatment plans based on individual genetic profiles, enabling precise targeting of therapy and minimizing adverse effects. Advances in molecular diagnostics, including genetic testing and next-generation sequencing (NGS), facilitate early diagnosis and patient stratification, which enhances outcomes by matching the most appropriate therapies to patient-specific characteristics.

Coagulation Disorders Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.8% over the forecast period (2025-2032)

Based on Type segmentation, Hemophilia A is predicted to show maximum market share in the year 2024

Based on Treatment segmentation, Blood Transfusion is the leading Treatment in 2024

Based on Test segmentation, Prothrombin Time Test is the leading Test in 2024

Based on End Users segmentation, Hospitals is the leading End Users in 2024

On the basis of region, Asia Pacific is the leading revenue generator in 2024

Coagulation Disorders Market- Segmentation Analysis:

The Global Coagulation Disorders Market is segmented on the basis of Type, Treatment, Test, End Users, and Region.

The market is divided into five categories based on Type: Hemophilia A, Hemophilia B, Von Willebrand's Disease, Factor II, V, X, XII Deficiencies, and Others. Hemophilia A is a genetic disorder characterized by a deficiency of clotting factor VIII, while Hemophilia B involves a deficiency of factor IX with similar symptoms. Von Willebrand's Disease results from low or defective von Willebrand factor, affecting blood clotting and causing mucosal bleeding. Factor II, V, X, XII deficiencies are rare coagulation disorders involving other clotting factors, leading to variable bleeding symptoms.

The market is divided into three categories based on Treatment: Iron Supplementation, Blood Transfusion, and Others. Iron supplementation is used to address anemia related to chronic blood loss. On the other-hand, blood transfusion replaces lost blood and supports clotting factor restoration. Factor replacement therapy, desmopressin, clot-preserving medications, gene therapy, and non-factor therapies tailor treatment based on disorder type and severity.

Coagulation Disorders Market- Geographical Insights

The coagulation disorders market shows distinct geographical trends shaped by healthcare infrastructure, disease prevalence, and regional investments. North America dominates the market, owing to high prevalence rates of coagulation disorders, well-established healthcare systems, and robust research and development activities. Additionally, increasing investments in plasma collection centers further boost market growth. Europe holds the second-largest share, with countries like Germany, the UK, France, Italy, and Spain contributing significantly. The region experiences growth through extensive research collaborations, regulatory approvals, and high patient awareness. Aging populations and advancements in diagnostic capabilities contribute to rising demand for coagulation disorder management. The Asia-Pacific region is the fastest-growing, fueled by rising healthcare expenditures, rapid urbanization, and expanding healthcare infrastructure in China, India, and Japan. Due to restricted access to and awareness of healthcare, regions including the Middle East, Africa, and Latin America exhibit slower growth. However, they also exhibit tremendous potential as a result of ongoing healthcare advancements and international collaborations.

Coagulation Disorders Market- Competitive Landscape:

The coagulation disorders market competitive landscape is characterized by the presence of several key global players who are driving innovation through advanced therapies and diagnostic solutions. The key market players focus on developing innovative treatment options such as gene therapies, long-acting recombinant clotting factors, monoclonal antibodies, and biosimilars to improve patient outcomes and quality of life. For instance, in April 2024, Haemonetics Corporation, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TEG 6s hemostasis analyzer system's Global Hemostasis-HN assay cartridge. This new cartridge expanded the TEG 6s system's viscoelastic testing capabilities to include fully heparinized patients undergoing adult cardiovascular surgeries and liver transplantation. Additionally, the adoption of plasma-free recombinant products and advancements in gene editing technologies like CRISPR are key trends shaping competition. Companies are also investing in point-of-care diagnostic tools and wearable coagulation monitoring devices, fostering a shift towards personalized and convenient patient care. Strategic collaborations, mergers, and acquisitions are common as companies strive to expand their product portfolios and regional presence.

Recent Developments:

In July 2025, Bio-Rad Laboratories, Inc. declared the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include Bio-Rad's QX Continuum droplet digital PCR (ddPCR) system, designed for translational research applications with a simplified, qPCR-like workflow, four-color multiplexing, and up to eight discrete thermal profiles per plate. With this launch, Bio-Rad's expanded portfolio of instruments, reagents, software, and services broadens its footprint in genomics research and applied science markets

In September 2025, VarmX B.V. is collaborated with CSL for the development of VMX-C001, a treatment restoring coagulation in patients on FXa DOACs. This treatment is intended to be administered as a single-dose infusion in emergency settings, such as severe bleeding or urgent surgery, where quick restoration of clotting is critical.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL COAGULATION DISORDERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Griflos S.A
  • Hoffman-La Roche Ltd
  • Bio-Rad Laboratories
  • B Braun
  • Abbott
  • Bayer AG
  • Helena Laboratories
  • Fresenius Kabi
  • Haemonetics Corporation
  • VarmX B.V.
  • Biogen Inc.
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand's Disease
  • Factor II, V, X, XII Deficiencies
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Iron Supplementation
  • Blood Transfusion
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY TEST- MARKET ANALYSIS, 2019 - 2032

  • Complete Blood Count (CBC)
  • Platelet Aggregation Test
  • Fibrinogen Assay
  • Prothrombin Time Test
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY END USERS- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Blood Banks
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Coagulation Disorders Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Coagulation Disorders Market Snippet by Type
    • 2.1.2. Coagulation Disorders Market Snippet by Treatment
    • 2.1.3. Coagulation Disorders Market Snippet by Test
    • 2.1.4. Coagulation Disorders Market Snippet by End Users
    • 2.1.5. Coagulation Disorders Market Snippet by Country
    • 2.1.6. Coagulation Disorders Market Snippet by Region
  • 2.2. Competitive Insights

3. Coagulation Disorders Key Market Trends

  • 3.1. Coagulation Disorders Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Coagulation Disorders Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Coagulation Disorders Market Opportunities
  • 3.4. Coagulation Disorders Market Future Trends

4. Coagulation Disorders Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Coagulation Disorders Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Coagulation Disorders Market Landscape

  • 6.1. Coagulation Disorders Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Coagulation Disorders Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Hemophilia A
    • 7.1.3. Hemophilia B
    • 7.1.4. Von Willebrand's Disease
    • 7.1.5. Factor II, V, X, XII Deficiencies
    • 7.1.6. Others

8. Coagulation Disorders Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
    • 8.1.2. Iron Supplementation
    • 8.1.3. Blood Transfusion
    • 8.1.4. Others

9. Coagulation Disorders Market - By Test

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Test, 2024 & 2032 (%)
    • 9.1.2. Complete Blood Count (CBC)
    • 9.1.3. Platelet Aggregation Test
    • 9.1.4. Fibrinogen Assay
    • 9.1.5. Prothrombin Time Test
    • 9.1.6. Others

10. Coagulation Disorders Market - By End Users

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End Users, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Diagnostic Centers
    • 10.1.5. Blood Banks
    • 10.1.6. Others

11. Coagulation Disorders Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Coagulation Disorders Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Coagulation Disorders Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Coagulation Disorders Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Coagulation Disorders Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Coagulation Disorders Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Coagulation Disorders Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Griflos S.A
    • 12.2.2. Hoffman-La Roche Ltd
    • 12.2.3. Bio-Rad Laboratories
    • 12.2.4. B Braun
    • 12.2.5. Abbott
    • 12.2.6. Bayer AG
    • 12.2.7. Helena Laboratories
    • 12.2.8. Fresenius Kabi
    • 12.2.9. Haemonetics Corporation
    • 12.2.10. VarmX B.V.
    • 12.2.11. Biogen Inc.
    • 12.2.12. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us